日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Targeting Wnt/β-catenin and circadian regulator restores PRC2/EZH2-controlled chromatin bivalency and suppresses cell state diversity

靶向Wnt/β-catenin和昼夜节律调节因子可恢复PRC2/EZH2控制的染色质二价性并抑制细胞状态多样性

Yang, Yatian; Zhang, Xiong; Venkadakrishnan, Varadha Balaji; Zou, Hongye; Zheng, Xingling; Guo, Shiyao; Chen, Christopher Z; Borowsky, Alexander D; Corey, Eva; Evans, Ronald M; Gao, Allen C; Dall'Era, Marc A; Zoubeidi, Amina; Lara, Primo N; Kung, Hsing-Jien; Chen, Xinbin; Beltran, Himisha; Chen, Hong-Wu

A clinical-stage oncology compound selectively targets drug-resistant cancers

一种处于临床阶段的肿瘤化合物可选择性地靶向耐药性癌症。

Long, Kaitlin; Bhattacharjee, Debanjan; Newman-Stonebraker, Samuel H; Suhr, Simon; Mercado, Brandon Q; Scheib, Emily; Tighe, Anthony; Romero, Luciano; Thompson, Sarah L; Sausville, Erin L; John, Kristen M; Julian, Linda; Mishra, Sanat; Klingbeil, Olaf; Gupta, Punya; Bhatt, Uditi; Gao, Allen C; Ricardo, Sara; Vakoc, Christopher R; Bornhauser, Beat C; Corsello, Steven M; Taylor, Stephen S; Chen, Jue; Holland, Patrick L; Sheltzer, Jason M

Correction: Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer

更正:PTUPB 对 AKR1C3 和雄激素受体轴的新型抑制作用可增强恩扎卢胺治疗晚期前列腺癌的效果

Yang, Joy C; Xu, Pengfei; Ning, Shu; Wasielewski, Logan J; Adomat, Hans; Hwang, Sung Hee; Morisseau, Christophe; Gleave, Martin; Corey, Eva; Gao, Allen C; Lara, Primo N Jr; Evans, Christopher P; Hammock, Bruce D; Liu, Chengfei

IGFBP3-SphK1/S1P Signaling Axis Drives Enzalutamide Resistance in Advanced Prostate Cancer

IGFBP3-SphK1/S1P信号轴驱动晚期前列腺癌的恩扎卢胺耐药性

Leslie, Amy R; Ning, Shu; Sharifi, Masuda; Schaaf, Zachary A; Maine, James P; Lou, Wei; Leslie, Kristina D; Liu, Chengfei; Xu, Hongyu; Lombard, Alan P; Chen, Hong-Wu; Parikh, Mamta; Dall'Era, Marc; Gao, Allen C

Inhibition of Galectin-1 and Androgen Receptor Axis Enhances Enzalutamide Treatment in Enzalutamide Resistant Prostate Cancer

抑制半乳糖凝集素-1和雄激素受体轴可增强恩扎卢胺治疗耐药性前列腺癌的效果

Wang, Hsiao-Chi; Gao, Allen C; Xia, Roger; Wu, Chun-Te; Hsu, Ssu-Wei; Chen, Ching-Hsien; Shih, Tsung-Chieh

Dynamic Reprogramming of Immune-Related Signaling During Progression to Enzalutamide Resistance in Prostate Cancer.

前列腺癌恩扎卢胺耐药进展过程中免疫相关信号的动态重编程。

Xu Pengfei, Qu Huan, Yang Joy C, Wei Fan, Zhao Junwei, Tang Menghuan, Wang Leyi, Nip Christopher, Li Henson, Gao Allen C, Lam Kit, Dall'Era Marc, Li Yuanpei, Liu Chengfei

Steroid Sulfatase Regulates Metabolic Reprogramming in Advanced Prostate Cancer.

类固醇硫酸酯酶调节晚期前列腺癌的代谢重编程

Sharifi Masuda, Armstrong Cameron M, Ning Shu, Leslie Amy R, Schaaf Zachary A, Maine James P, Lou Wei, Li Pui-Kai, Xu Hongyu, Liu Chengfei, Gao Allen C

LX1 Dual Targets AR Variants and AKR1C3 in Advanced Prostate Cancer Therapy.

LX1 双靶点 AR 变异体和 AKR1C3 在晚期前列腺癌治疗中的应用

Ning Shu, Armstrong Cameron M, Xing Enming, Leslie Amy R, Gao Richard Y, Sharifi Masuda, Schaaf Zachary A, Lou Wei, Han Xiangrui, Xu Desiree H, Yang Rui, Cheng Jeffrey, Mohammed Shabber, Mitsiades Nicholas, Liu Chengfei, Lombard Alan P, Wu Chun-Yi, Cheng Xiaolin, Li Pui-Kai, Gao Allen C

Correction: Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer

更正:尼克酰胺通过抑制去势抵抗性前列腺癌中的雄激素受体变体来增强阿比特龙的治疗效果

Liu, Chengfei; Armstrong, Cameron; Zhu, Yezi; Lou, Wei; Gao, Allen C

Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer

晚期前列腺癌的治疗耐药模型和治疗顺序

Schaaf, Zachary A; Ning, Shu; Leslie, Amy R; Sharifi, Masuda; Han, Xianrui; Armstrong, Cameron; Lou, Wei; Lombard, Alan P; Liu, Chengfei; Gao, Allen C